Europlasma Société Anonyme announced audited consolidated earnings results for the year ended December 31, 2015. Consolidated revenue amounted to 14.1 million for the 2015 financial year against 8.983 million a year ago. The 5.1 million increase, that is 57% for the year, was driven by revenue growth in each of the Group's segments.
The operating loss for 2015 stood at 14.6 million against 22.940 million a year ago. The 8.3 million improvement compared with 2014 is due, on the one hand, to a significant reduction in depreciation, amortisation, impairment and provisions over the period, and on the other hand, to the more solid operating performance. LBITDA was 9 million compared with 11.2 million in 2014.
This improvement in performance was driven by each of the segments, which all posted positive contributions to this change. In total, the loss is standing at 16.2 million, compared with 26 million in 2014, a reduction of 38%. Net debt was 5,709,000.
Net cash used in operating activities was 11.996 million compared with 13.083 million in 2014.